Johnson & Johnson (JNJ) came out with quarterly earnings of $2.04 per share, beating the Zacks Consensus Estimate of $2 per share. This compares to earnings of $2.29 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 2%. A quarter ago, it was expected that this world's biggest maker of health care products would post earnings of $2.22 per share when it actually produced earnings of $2.42, delivering a surprise of 9.01%.Over the l ...

Worldwide Sales Performance - Worldwide sales increased by 5.3% to $22,520 million in Q4 2024 compared to $21,395 million in Q4 2023, driven by a 10.0% growth in U.S. sales[1] - Worldwide sales excluding COVID-19 vaccine increased by 5.5% to $22,520 million in Q4 2024 compared to $21,351 million in Q4 2023[2] - Worldwide sales for the twelve months increased by 4.3% to $88,821 million in 2024 compared to $85,159 million in 2023[4] - Worldwide sales excluding COVID-19 vaccine for the twelve months increased by 5.5% to $88,623 million in 2024 compared to $84,042 million in 2023[5] - Sales to customers increased by 4.3% to $88,821 million in 2024 compared to $85,159 million in 2023[13] - Worldwide sales excluding COVID-19 Vaccine grew by 5.5% to $88,623 million, with operational growth of 7.0%[42] U.S. Sales Performance - U.S. sales grew by 10.0% to $13,204 million in Q4 2024, while Europe sales declined by 0.8% to $4,921 million[1] - Innovative Medicine segment sales grew by 4.4% to $14,332 million in Q4 2024, with U.S. sales increasing by 11.1% to $8,977 million[7] - MedTech segment sales increased by 6.7% to $8,188 million in Q4 2024, driven by a 7.6% growth in U.S. sales to $4,227 million[7] - Adjusted operational sales growth for the Innovative Medicine segment was 6.1% worldwide in Q4 2024, with U.S. growth of 11.1%[23] - MedTech segment's adjusted operational sales growth was 7.6% worldwide in Q4 2024, driven by 7.6% growth in both U.S. and international markets[23] - Innovative Medicine segment reported a 4.0% growth worldwide, with U.S. growth at 9.0% and International decline at (2.5)%[25] - MedTech segment showed a 4.8% growth worldwide, with U.S. growth at 6.9% and International growth at 2.6%[25] - Oncology segment sales grew by 19.0% worldwide, driven by a 32.2% increase in U.S. sales[30] - DARZALEX sales increased by 20.9% worldwide, with U.S. sales up 28.9% and International sales up 11.3%[30] - SPRAVATO sales surged by 44.6% worldwide, with U.S. sales up 50.1%[30] - CARVYKTI sales showed significant growth, with U.S. sales at $304 million and International sales at $31 million[30] - Innovative Medicine segment worldwide sales increased by 4.4% to $14,332 million, with US sales growing 11.1% to $8,977 million and international sales declining 5.1% to $5,355 million[31] - Pulmonary Hypertension products worldwide sales grew 7.4% to $1,092 million, driven by 11.6% growth in US sales to $819 million[31] - Xarelto worldwide sales surged 28.5% to $676 million, entirely from US market growth[31] - MedTech segment worldwide sales increased 6.7% to $8,188 million, with US sales up 7.6% to $4,227 million and international sales growing 5.8% to $3,961 million[33] - Cardiovascular products within MedTech segment saw 23.6% worldwide sales growth to $2,062 million, with US sales jumping 25.8% to $1,221 million[32] - Contact Lenses/Other products worldwide sales rose 6.3% to $937 million, with US sales up 6.0% to $396 million[33] - Innovative Medicine segment total worldwide sales increased by 4.0% to $56,964 million in 2024, with US sales growing 9.0% to $33,970 million and international sales declining 2.5% to $22,994 million[38] - US sales of CARVYKTI surged 85.2% to $869 million, contributing to overall Oncology segment growth in the US market[37] - SPRAVATO US sales increased 57.8% to $929 million, driving Neuroscience segment growth in the US market[37] - XARELTO sales remained stable worldwide at $2,373 million, with US sales growing slightly by 0.3%[38] - US MedTech sales grew by 6.9% to $16,332 million, contributing significantly to overall segment performance[40] International Sales Performance - International sales decreased by 0.7% to $9,316 million in Q4 2024, with Western Hemisphere excluding U.S. sales dropping by 2.7% to $1,135 million[1] - Innovative Medicine segment worldwide sales increased by 4.4% to $14,332 million, with US sales growing 11.1% to $8,977 million and international sales declining 5.1% to $5,355 million[31] - MedTech segment worldwide sales increased 6.7% to $8,188 million, with US sales up 7.6% to $4,227 million and international sales growing 5.8% to $3,961 million[33] - Vision products worldwide sales increased 7.9% to $1,303 million, with international sales growing 10.2% to $794 million[33] - Surgical products worldwide sales increased 12.4% to $365 million, driven by 19.3% growth in international sales to $252 million[33] - Innovative Medicine segment total worldwide sales increased by 4.0% to $56,964 million in 2024, with US sales growing 9.0% to $33,970 million and international sales declining 2.5% to $22,994 million[38] - International sales of TREMFYA grew 22.8% to $1,227 million, outperforming the overall Immunology segment's international performance[35] - International MedTech sales increased by 2.6% to $15,525 million, with operational growth of 5.4%[40] Segment Performance - Innovative Medicine segment sales grew by 4.4% to $14,332 million in Q4 2024, with U.S. sales increasing by 11.1% to $8,977 million[7] - MedTech segment sales increased by 6.7% to $8,188 million in Q4 2024, driven by a 7.6% growth in U.S. sales to $4,227 million[7] - Adjusted operational sales growth for the Innovative Medicine segment was 6.1% worldwide in Q4 2024, with U.S. growth of 11.1%[23] - MedTech segment's adjusted operational sales growth was 7.6% worldwide in Q4 2024, driven by 7.6% growth in both U.S. and international markets[23] - Innovative Medicine segment reported a 4.0% growth worldwide, with U.S. growth at 9.0% and International decline at (2.5)%[25] - MedTech segment showed a 4.8% growth worldwide, with U.S. growth at 6.9% and International growth at 2.6%[25] - Immunology segment sales declined by 7.8% worldwide, with U.S. sales down 5.9% and International sales down 11.5%[28] - Oncology segment sales grew by 19.0% worldwide, driven by a 32.2% increase in U.S. sales[30] - DARZALEX sales increased by 20.9% worldwide, with U.S. sales up 28.9% and International sales up 11.3%[30] - SPRAVATO sales surged by 44.6% worldwide, with U.S. sales up 50.1%[30] - CARVYKTI sales showed significant growth, with U.S. sales at $304 million and International sales at $31 million[30] - Adjusted operational sales growth excluding acquisitions, divestitures, and COVID-19 vaccine was 7.6% for Innovative Medicine and 4.7% for MedTech[25] - Innovative Medicine segment worldwide sales increased by 4.4% to $14,332 million, with US sales growing 11.1% to $8,977 million and international sales declining 5.1% to $5,355 million[31] - Pulmonary Hypertension products worldwide sales grew 7.4% to $1,092 million, driven by 11.6% growth in US sales to $819 million[31] - Xarelto worldwide sales surged 28.5% to $676 million, entirely from US market growth[31] - MedTech segment worldwide sales increased 6.7% to $8,188 million, with US sales up 7.6% to $4,227 million and international sales growing 5.8% to $3,961 million[33] - Cardiovascular products within MedTech segment saw 23.6% worldwide sales growth to $2,062 million, with US sales jumping 25.8% to $1,221 million[32] - Vision products worldwide sales increased 7.9% to $1,303 million, with international sales growing 10.2% to $794 million[33] - Contact Lenses/Other products worldwide sales rose 6.3% to $937 million, with US sales up 6.0% to $396 million[33] - Orthopaedics worldwide sales grew 2.1% to $2,315 million, with Hips products increasing 5.2% to $418 million worldwide[32] - Surgical products worldwide sales increased 12.4% to $365 million, driven by 19.3% growth in international sales to $252 million[33] - Abiomed products worldwide sales grew 12.9% to $384 million, with US sales increasing 11.3% to $308 million[32] - Innovative Medicine segment total worldwide sales increased by 4.0% to $56,964 million in 2024, with US sales growing 9.0% to $33,970 million and international sales declining 2.5% to $22,994 million[38] - Oncology segment sales grew 17.7% worldwide to $20,781 million, driven by strong performance of CARVYKTI (92.7% growth to $963 million) and DARZALEX (19.8% growth to $11,670 million)[37] - Immunology segment sales declined 1.2% worldwide to $17,828 million, with TREMFYA showing strong growth of 16.6% to $3,670 million while STELARA declined 4.6% to $10,361 million[35] - Neuroscience segment sales remained flat worldwide at $7,115 million, with SPRAVATO showing significant growth of 56.4% to $1,077 million[37] - Pulmonary Hypertension segment sales increased 12.3% worldwide to $4,282 million, led by OPSUMIT (10.7% growth to $2,184 million) and UPTRAVI (14.9% growth to $1,817 million)[38] - MedTech segment worldwide sales increased by 4.8% to $31,857 million, with operational growth of 6.2%[40] - Cardiovascular segment worldwide sales grew by 21.4% to $7,707 million, driven by strong US growth of 24.2%[39] - Orthopaedics segment worldwide sales rose by 2.4% to $9,158 million, with US sales increasing by 3.0%[39] - Vision segment worldwide sales increased by 1.5% to $5,146 million, with US sales growing by 2.0%[40] - Innovative Medicine worldwide sales grew by 4.4% to $14,332 million, with US sales up 11.1%[41] Financial Performance - Net earnings from Continuing Operations decreased by 17.0% to $3,431 million in Q4 2024 compared to $4,132 million in Q4 2023[11] - Research and development expenses increased by 18.3% to $5,298 million in Q4 2024, representing 23.5% of sales[11] - Gross profit rose by 4.7% to $61,350 million in 2024, with a gross margin of 69.1%[13] - Research and development expense increased by 14.2% to $17,232 million in 2024, representing 19.4% of sales[13] - Net earnings from Continuing Operations grew by 5.6% to $14,066 million in 2024, with a diluted EPS increase of 11.3% to $5.79[13] - Adjusted net earnings from Continuing Operations decreased by 4.6% to $24,242 million in 2024, with a diluted EPS of $9.98[13] - The company incurred $167 million in restructuring costs in 2024 related to the Orthopaedics franchise streamlining[17] - COVID-19 vaccine-related costs totaled $100 million in 2024, primarily for external manufacturing network exit and clinical trial expenses[18] - European Medical Device Regulation (MDR) compliance costs amounted to $204 million in 2024, with implementation substantially completed by Q4 2024[18] COVID-19 Vaccine Impact - Worldwide sales excluding COVID-19 vaccine increased by 5.5% to $22,520 million in Q4 2024 compared to $21,351 million in Q4 2023[2] - Worldwide sales excluding COVID-19 vaccine for the twelve months increased by 5.5% to $88,623 million in 2024 compared to $84,042 million in 2023[5] - COVID-19 vaccine contributed 1.8% to Innovative Medicine's growth, with International impact at 4.2%[25] - COVID-19 vaccine sales plummeted 82.4% worldwide to $198 million in 2024[35] - COVID-19 Vaccine sales declined by 82.4% worldwide to $198 million, reflecting reduced demand[42] Europe Sales Performance - Europe sales excluding COVID-19 Vaccine increased by 3.7% to $20,014 million, driven by operational growth of 4.1%[42]

Earnings Season Overview - The 2024 Q4 earnings season has gained momentum with several consumer staples giants set to report, including Procter & Gamble (PG), Johnson & Johnson (JNJ), and Kimberly-Clark (KMB) [1] Procter & Gamble (PG) - PG shares have declined approximately 3% over the past six months but modestly outperformed the Zacks Consumer Staples sector [3] - Analysts have shown bearish sentiment, with the Zacks Consensus EPS estimate of $1.86 down 2% over recent months, suggesting 1% YoY growth [3] - Forecasted sales of $21.6 billion are 0.7% higher than the year-ago figure [3] - Gross margin expansion has strengthened profitability, and the company reaffirmed its current year guidance [5] - Valuation is in line with historical levels, with a forward 12-month earnings multiple of 22.5X and a PEG ratio of 3.5X [7] - The stock has a Style Score of 'D' for Value [7] Johnson & Johnson (JNJ) - JNJ shares have declined 2% over the past six months but outperformed the Zacks Consumer Staples sector [8] - Analysts have shown slight bearishness, with the Zacks Consensus EPS estimate of $2.00 down modestly, suggesting a 13% YoY decline [8] - Sales are expected to grow 5.3% YoY [8] - Margins have come under pressure, contributing to declining profitability and EPS [10] - Valuation is more attractive than PG, with a forward 12-month earnings multiple of 13.9X and a PEG ratio of 2.4X [12] - The stock has a Style Score of 'B' for Value [13] Kimberly-Clark (KMB) - KMB shares have declined roughly 10% over the past six months, underperforming the Zacks Consumer Staples sector [14] - The EPS outlook remains stable at $1.50 per share, suggesting flat YoY growth [14] - Revenue is expected to decline 3% YoY [14] - Margins have expanded, but this has been largely ignored by investors, with shares remaining flat over a three-year timeframe [16] - Valuation is fair, with a forward 12-month earnings multiple of 16.7X and a PEG ratio of 3.6X [18] - The stock has a Style Score of 'C' for Value [18] Key Themes for Earnings Releases - Margins and top-line growth will be critical factors to watch in the upcoming earnings releases of PG, JNJ, and KMB [20] - Given the defensive nature of these companies, significant post-earnings volatility is unlikely [20]

Johnson & Johnson JNJ will be reporting its fourth-quarter earnings on Wednesday. Wall Street expects $2 in EPS and $22.44 billion in revenues as the company reports before market hours.The stock is down 8.88% over the past year, up 2.79% YTD.Johnson & Johnson's Spravato Wins FDA Nod Ahead Of EarningsJohnson & Johnson has secured FDA approval for expanded use of its Spravato nasal spray, now cleared as a standalone treatment for adults with major depressive disorder who failed at least two oral antidepressa ...

Investors Who Lost Money on Johnson & Johnson Should Contact Levi & Korsinsky About an Ongoing Investigation - JNJ ...

Bronstein, Gewirtz & Grossman, LLC Is Investigating Johnson & Johnson (JNJ) And Encourages Shareholders to Connect ...

The Food and Drug Administration on Tuesday approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow. The spray, called Spravato, is now the first-ever standalone therapy for treatment-resistant depression, which is when trying at least two standard treatments does little to nothing to improve depression symptoms in a patient. Previously, Spravato was cleared in the U.S. to use together with an oral antidepress ...

Following U.S. FDA Priority Review, approval is based on data demonstrating SPRAVATO® alone met its primary endpoint at 4 weeks and led to rapid and superior improvement in depressive symptoms compared to placebo as early as 24 hours1  SPRAVATO® alone showed a rapid and superior improvement vs. placebo in the Montgomery-Asberg Depression Rating Scale (MADRS) total score, with numerical improvements across all 10 MADRS items seen at day 28 in a post-hoc analysis2Monotherapy data adds to well-established clin ...

Earnings and Estimates - The Zacks Consensus Estimate for JNJ Q4 sales and earnings is $22.5 billion and $2.01 per share, respectively [1] - The Zacks Consensus Estimate for JNJ's 2024 earnings has risen from $9.93 to $9.95 per share, while the 2025 estimate has declined from $10.54 to $10.50 per share over the past 60 days [2] - JNJ has exceeded earnings expectations in each of the trailing four quarters, with an average four-quarter earnings surprise of 4.15% [5][6] Stock Performance - JNJ stock has declined 9.5% in the past year, compared to a 5.4% decrease for the industry [1][17] - The stock has underperformed the sector and the S&P 500 [17] - JNJ shares currently trade at 13.95 forward earnings, lower than the industry's 15.29 and the stock's 5-year mean of 16.02 [19] Innovative Medicines Segment - Sales are expected to be driven by key products such as Darzalex, Tremfya, and Erleada [8] - The Zacks Consensus Estimate for Darzalex sales is $3.04 billion, while the model estimate is $3.06 billion [8] - The Zacks Consensus Estimate for Tremfya sales is $1.06 billion, while the model estimate is $1.09 billion [8] - The Zacks Consensus Estimate for Erleada sales is $793.8 million, while the model projects $805.0 million [9] - New drugs like Carvykti, Tecvayli, Talvey, and Spravato are likely to have contributed to top-line growth [9] MedTech Segment - Sales in the Asia Pacific region, specifically China, were hurt by the volume-based procurement program and anti-corruption campaign [13] - JNJ does not expect improvement in the Asia Pacific region in Q4 2024, but new product uptake and commercial execution are expected to boost growth in other markets [14] - The Zacks Consensus Estimate for the MedTech segment is $8.28 billion, while the model estimate is $8.23 billion [14] Acquisitions and Pipeline - JNJ completed acquisitions of Shockwave and V-Wave in MedTech, and Ambrx, Proteologix, and NM26 bispecific antibody in Innovative Medicine [23] - JNJ announced a definitive agreement to acquire Intra-Cellular Therapies for $14.6 billion, adding Caplyta and other CNS candidates to its pipeline [24] Challenges - Sales of key drug Stelara declined in Q3 2024 due to unfavorable patient mix and share loss in Europe [10] - Several biosimilar versions of Stelara are expected to be launched in the US in 2025 [11] - Imbruvica sales are likely to have declined due to rising competitive pressure in the US [12] - JNJ faces more than 62,000 lawsuits related to its talc-based products [25] Outlook - JNJ's outlook for 2025 looks positive, with growth expected in the Innovative Medicine segment driven by key products and new drugs [26] - In MedTech, operational sales growth is expected to be at the upper end of the 5-7% long-term guided range, driven by new product launches and acquisitions [26]

Johnson & Johnson (JNJ) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates ...